Dec 7th 2013, 04:30, by Josh Lowensohn
The Food and Drug Administration has approved a new drug that promises to treat hepatitis C with a daily pill instead of the more common weekly injection. The drug, called Sovaldi from Gilead Sciences, has been designed to block the protein hepatitis C uses to replicate itself. The treatment does not come cheap, though. According to The New York Times, a 12-week therapy — which is suggested for most patients — runs $84,000, or $1,000 per day, and can stretch to 24 weeks for more aggressive treatments.
Continue reading…
No comments:
Post a Comment